Response of Patients with Taxane-Refractory Advanced Urothelial Cancer to Enfortumab Vedotin, a Microtubule-Disrupting Agent

Enfortumab vedotin (EV), a nectin-4-directed antibody conjugated to monomethyl auristatin E (MMAE), has been approved for patients with advanced urothelial carcinoma (aUC) previously treated with platinum-based chemotherapy and immune inhibitors. Taxane agents and MMAE share antitumor mechanisms thr...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyake, Makito, Nishimura, Nobutaka, Miyamoto, Tatsuki, Shimizu, Takuto, Ohnishi, Kenta, Hori, Shunta, Morizawa, Yosuke, Gotoh, Daisuke, Nakai, Yasushi, Torimoto, Kazumasa, Fujii, Tomomi, Fujimoto, Kiyohide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9867573/
https://www.ncbi.nlm.nih.gov/pubmed/36691441
http://dx.doi.org/10.1155/2023/1024239

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9867573/
https://www.ncbi.nlm.nih.gov/pubmed/36691441
http://dx.doi.org/10.1155/2023/1024239

Ejemplares similares